% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Heidegger:282500,
      author       = {S. Heidegger and F. Stritzke and S. Dahl and J.
                      Daßler-Plenker and L. Joachim and D. Buschmann and K. Fan
                      and C. M. Sauer and N. Ludwig and C. Winter$^*$ and S.
                      Enssle and S. Li and M. Perl and A. Görgens and T. Haas and
                      E. T. Orberg$^*$ and S. Göttert and C. Wölfel$^*$ and T.
                      Engleitner and I. Cortés-Ciriano and R. Rad$^*$ and W. Herr
                      and B. Giebel and J. Ruland$^*$ and F. Bassermann$^*$ and C.
                      Coch and G. Hartmann and H. Poeck},
      title        = {{T}argeting nucleic acid sensors in tumor cells to
                      reprogram biogenesis and {RNA} cargo of extracellular
                      vesicles for {T} cell-mediated cancer immunotherapy.},
      journal      = {Cell reports / Medicine},
      volume       = {4},
      number       = {9},
      issn         = {2666-3791},
      address      = {Maryland Heights, MO},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-01789},
      pages        = {101171},
      year         = {2023},
      note         = {2023 Sep 19;4(9):101171},
      abstract     = {Tumor-derived extracellular vesicles (EVs) have been
                      associated with immune evasion and tumor progression. We
                      show that the RNA-sensing receptor RIG-I within tumor cells
                      governs biogenesis and immunomodulatory function of EVs.
                      Cancer-intrinsic RIG-I activation releases EVs, which
                      mediate dendritic cell maturation and T cell antitumor
                      immunity, synergizing with immune checkpoint blockade.
                      Intact RIG-I, autocrine interferon signaling, and the GTPase
                      Rab27a in tumor cells are required for biogenesis of
                      immunostimulatory EVs. Active intrinsic RIG-I signaling
                      governs composition of the tumor EV RNA cargo including
                      small non-coding stimulatory RNAs. High transcriptional
                      activity of EV pathway genes and RIG-I in melanoma samples
                      associate with prolonged patient survival and beneficial
                      response to immunotherapy. EVs generated from human melanoma
                      after RIG-I stimulation induce potent antigen-specific T
                      cell responses. We thus define a molecular pathway that can
                      be targeted in tumors to favorably alter EV immunomodulatory
                      function. We propose 'reprogramming' of tumor EVs as a
                      personalized strategy for T cell-mediated cancer
                      immunotherapy.},
      keywords     = {RIG-I (Other) / RNA (Other) / STING (Other) / cancer
                      immunotherapy (Other) / cancer resistance (Other) /
                      extracellular vesicles (Other) / innate immunity (Other) /
                      nucleic acid receptors (Other) / personalized therapy
                      (Other)},
      cin          = {MU01 / FM01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331 / I:(DE-He78)FM01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37657445},
      doi          = {10.1016/j.xcrm.2023.101171},
      url          = {https://inrepo02.dkfz.de/record/282500},
}